2.600USD+8.33%Mkt Cap: 238.89M USDP/E: —Last update: 2026-05-22
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap238.89M USD
Enterprise Value166.26M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-36.12M USD
Revenue/Share—
Last Price2.600 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.56
PEG—
EV/EBITDA-3.82
EV/Revenue—
P/S—
P/B4.23
EPS (TTM)-0.42
EPS (Forward)-0.43
52W Range
0.490067% of range3.620
52W High3.620 USD
52W Low0.4900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.73%
ROA-52.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.39M USD
CapEx (TTM)2.03M USD
FCF Margin—
FCF Yield-9.96%
Net Debt-54.25M USD
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity0.00
Current Ratio8.96
Quick Ratio8.35
Book Value/Sh0.5680 USD
Cash/Share0.5930 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)6.000 USD
Target Range4.000 USD – 9.000 USD
# Analysts8
Ownership
Shares Out.91.88M
Float42.82M
Insiders1.18%
Institutions81.31%
Short Interest
Short Ratio1.0d
Short % Float1.13%
Short % Out.0.98%
Shares Short898.68K
Short (prev mo.)1.11M
Technical
SMA 502.536 (+2.5%)
SMA 2001.685 (+54.3%)
Beta1.57
S&P 52W Chg28.31%
Avg Vol (30d)866.05K
Avg Vol (10d)521.65K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—